Chimeric monoclonal antibodies which neutralize HIV-1 infection and their applications in therapy and prevention for AIDS
US5981278A · kind A · utility
4Cited by
4References
6Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 26, 1991 |
| Grant date | Nov 9, 1999 |
| Priority date | — |
| Expiry date | Sep 26, 2011 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2740/16122
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Monoclonal antibodies are revealed which bind to the gp 120 protein on the envelope of HIV-1. These antibodies neutralize HIV-1. They inhibit the rate of infection of T cells, and also inhibit syncytium formation. Further, the antibodies are group-specific and neutralize different strains and isolates of HIV-1. These antibodies have a variety of uses, including the treatment and prevention of AIDS and ARC.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.